Pull to refresh
Logo
Daily Brief
Following Why Sign Up
New CRISPR-engineered cancer models decode how tumors outsmart targeted therapies

New CRISPR-engineered cancer models decode how tumors outsmart targeted therapies

New Capabilities
By Newzino Staff |

ATCC and the Broad Institute release 13 isogenic cell lines replicating osimertinib resistance, building toward a systematic map of how cancers fight back against drugs

Tomorrow: Findings presented at AACR Annual Meeting

Overview

Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most of them will respond. Nearly all of them will eventually stop responding, as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers trying to understand those escape routes had to work with messy, inconsistent lab models that made it difficult to pin down which genetic change caused which failure. On April 20, 2026, the American Type Culture Collection (ATCC) and the Broad Institute of MIT and Harvard released a panel of 13 precisely engineered cancer cell lines, each genetically identical except for a single, defined resistance mechanism, giving researchers clean, standardized tools to study exactly how and why treatments stop working.

Why it matters

Cancer drug resistance kills more patients than cancer drug failure, and researchers now have the first standardized toolkit to decode it systematically.

Key Indicators

13
Isogenic cell line models released
Each engineered with a single, defined resistance mechanism to osimertinib, enabling direct comparison against the sensitive parent line.
$7.25B
Osimertinib annual sales (2025)
AstraZeneca's Tagrisso is one of the world's best-selling cancer drugs, underscoring how many patients depend on a therapy that eventually fails.
18–24 mo
Typical time to resistance
Most patients on first-line osimertinib develop resistance within two years, with no single dominant escape mechanism.
1,000+
Cell lines in DepMap
The Broad's Cancer Dependency Map has profiled over a thousand cancer cell lines; the new resistance models expand this resource into a new dimension.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

KW
Kirsty Wienand
Lead researcher on the isogenic resistance model project
FV
Francisca Vazquez
Overseeing integration of resistance models into DepMap and ResMap
MG
Mindy Goldsborough
Leading ATCC's cancer model engineering and distribution efforts

Organizations Involved

ATCC (American Type Culture Collection)
ATCC (American Type Culture Collection)
Biological Standards Organization
Co-developed and will distribute the isogenic resistance models

The world's premier repository for authenticated, quality-controlled biological materials, including more than 4,000 human and animal cell lines used in research worldwide.
Broad Institute of MIT and Harvard
Broad Institute of MIT and Harvard
Biomedical Research Institute
Co-developed models and will host genomic data on DepMap portal

A genomics-focused research institute that runs the Cancer Dependency Map (DepMap), the largest open-access effort to map genetic vulnerabilities across cancer cell lines.
AstraZeneca
AstraZeneca
Pharmaceutical Company
Maker of osimertinib (Tagrisso), the drug whose resistance the models replicate

The British-Swedish pharmaceutical company that developed osimertinib (sold as Tagrisso), which generated $7.25 billion in sales in 2025 as the standard of care for EGFR-mutant lung cancer.

Timeline

  1. Findings presented at AACR Annual Meeting

    Conference

    ATCC and Broad researchers presented "Engineering isogenic models harboring resistance mechanisms to the latest-generation EGFR inhibitor in non-small cell lung cancer" at the American Association for Cancer Research meeting in San Diego.

  2. ATCC and Broad release 13 CRISPR-engineered resistance models

    Research Milestone

    The collaboration published a panel of isogenic non-small cell lung cancer cell lines, each carrying a single defined resistance mechanism to osimertinib, along with associated genomic datasets available through the DepMap portal.

  3. Base editing screens map resistance genetics at scale

    Research Milestone

    Researchers used CRISPR base editing mutagenesis to prospectively identify genetic mechanisms of resistance to ten oncology drugs across cancer cell lines, demonstrating the feasibility of systematic resistance mapping.

  4. Amivantamab-lazertinib beats osimertinib in first-line trial

    Clinical

    The MARIPOSA trial showed that combining the bispecific antibody amivantamab with the EGFR inhibitor lazertinib extended progression-free survival to 23.7 months versus 16.6 months for osimertinib alone, validating the combination approach to overcoming resistance.

  5. Osimertinib becomes first-line standard of care

    Regulatory

    Based on the FLAURA trial showing nearly doubled progression-free survival compared to older drugs, osimertinib won approval as the preferred first treatment for EGFR-mutant non-small cell lung cancer.

  6. FDA approves osimertinib for resistant lung cancer

    Regulatory

    The Food and Drug Administration granted accelerated approval for AstraZeneca's third-generation EGFR inhibitor, initially for patients whose tumors acquired the T790M resistance mutation on earlier drugs.

  7. Cancer Cell Line Encyclopedia profiles 947 lines

    Research Milestone

    The Broad Institute and Novartis published comprehensive genomic characterization of nearly a thousand cancer cell lines, establishing the molecular foundation for linking genetic features to drug sensitivity.

  8. NCI launches the NCI-60 cancer cell line screen

    Research Milestone

    The National Cancer Institute introduced a standardized panel of 60 human cancer cell lines for drug screening, replacing decades of mouse-based testing and creating the first systematic framework for matching drugs to tumor types.

Scenarios

1

ResMap expands across tumor types, becomes standard drug development tool

Discussed by: Broad Institute leadership and DepMap collaborators, who have outlined plans to extend the isogenic resistance modeling approach beyond EGFR-mutant lung cancer to other targeted therapies and tumor types

The osimertinib resistance panel serves as proof of concept for a broader Response and Resistance Map. The Broad and ATCC extend the approach to other high-value drug-resistance pairs, such as CDK4/6 inhibitor resistance in breast cancer or BRAF inhibitor resistance in melanoma. Pharmaceutical companies and AI drug discovery platforms adopt the standardized models as required components of preclinical development, and regulatory agencies begin incorporating resistance profiling data into approval frameworks. This outcome is most likely if the initial models prove reproducible across labs and predictive of clinical resistance patterns.

2

AI-driven combination therapies identified using resistance models reach clinical trials

Discussed by: Computational oncology researchers and AI drug discovery companies including Recursion Pharmaceuticals and Insitro, who have highlighted the value of clean isogenic datasets for training predictive models

Machine learning programs trained on the isogenic resistance models and DepMap data identify specific drug combinations that block multiple escape routes simultaneously. Within two to three years, at least one combination strategy derived from these models enters clinical trials for osimertinib-resistant lung cancer. The clean genotype-phenotype relationships in the isogenic models prove far more useful for training algorithms than the noisy data from traditional dose-escalation resistance models.

3

Isogenic models fail to predict real-world resistance, limiting clinical impact

Discussed by: Cancer biologists who have noted the historical gap between in vitro models and patient tumor behavior, including critics of earlier standardized panels like the NCI-60

Despite elegant engineering, the single-mutation isogenic models prove too simple to capture the complexity of clinical resistance, which often involves multiple concurrent mechanisms, tumor microenvironment interactions, and immune system dynamics that cell lines cannot replicate. Researchers find that drug combinations effective against individual resistance mutations in the models fail when tumors deploy several escape routes simultaneously. The models remain useful for basic mechanistic studies but do not meaningfully accelerate clinical progress against resistance.

4

Fourth-generation EGFR inhibitors make osimertinib resistance less clinically urgent

Discussed by: Clinical oncologists tracking the MARIPOSA trial results and pharmaceutical companies developing next-generation combinations such as amivantamab plus lazertinib

Combination regimens that simultaneously target EGFR through multiple mechanisms, such as the amivantamab-lazertinib pairing that already showed superior results to osimertinib in the MARIPOSA trial, become the new standard of care. The resistance models remain scientifically valuable but their most immediate clinical motivation recedes as frontline treatment evolves. The ResMap framework proves more important for its methodology than for the specific osimertinib resistance question.

Historical Context

NCI-60 Human Tumor Cell Line Screen (1990)

1990–present

What Happened

The National Cancer Institute, led by Michael Boyd, replaced three decades of mouse-based drug screening with a panel of 60 human cancer cell lines representing nine tumor types. Over 100,000 compounds were screened through the panel, generating the largest cancer pharmacology database in the world and enabling the COMPARE algorithm for matching drug mechanisms of action.

Outcome

Short Term

The panel shifted cancer drug discovery from animal models to human cell-based screening and enabled identification of compounds active against specific tumor types for the first time.

Long Term

While the NCI-60 did not solve the problem of predicting clinical responses from lab data, it established the conceptual and methodological foundation for all subsequent large-scale cell line panels, including the Cancer Cell Line Encyclopedia and DepMap.

Why It's Relevant Today

The ATCC-Broad resistance models represent the next evolutionary step in the same trajectory: from screening compounds against tumors to systematically mapping how tumors defeat those compounds, using increasingly precise genetic tools.

Cancer Cell Line Encyclopedia launch (2012)

March 2012

What Happened

The Broad Institute and Novartis published comprehensive genomic profiles of 947 cancer cell lines in Nature, cataloging gene expression, chromosomal copy number, and mutations alongside drug response data for 24 compounds. The datasets were made freely available, establishing the molecular foundation for precision oncology research.

Outcome

Short Term

Researchers could, for the first time, systematically link specific genetic features in cancer cells to drug sensitivity or resistance at scale, enabling biomarker-driven drug development strategies.

Long Term

The CCLE became one of the most widely cited resources in cancer biology, directly enabling identification of therapeutic targets such as PRMT5 and WRN. It evolved into the DepMap portal, which now profiles over a thousand cell lines with CRISPR screens and drug sensitivity data.

Why It's Relevant Today

The new isogenic resistance models build directly on the CCLE and DepMap infrastructure. Where the CCLE cataloged what cancer cells are, and DepMap mapped what they depend on, the resistance models now catalog how they adapt when those dependencies are targeted.

Imatinib resistance in chronic myeloid leukemia (2001–2006)

2001–2006

What Happened

After imatinib (Gleevec) transformed chronic myeloid leukemia (CML) from a death sentence into a manageable disease, researchers identified the T315I "gatekeeper" mutation as a key resistance mechanism. This led to the systematic development of second-generation inhibitors dasatinib and nilotinib, and ultimately the third-generation inhibitor ponatinib that overcame the T315I mutation.

Outcome

Short Term

Understanding specific resistance mutations enabled rational design of drugs that worked in patients whose tumors had stopped responding to imatinib.

Long Term

The CML resistance story became the template for precision oncology's approach to drug resistance: identify the molecular escape route, then design a drug to block it. The same logic drove osimertinib's development to overcome T790M resistance in lung cancer.

Why It's Relevant Today

The ATCC-Broad models attempt to industrialize for osimertinib resistance what took years of ad hoc research for imatinib resistance. Where CML had one dominant escape route, osimertinib resistance involves at least a dozen, making standardized models essential for systematic study.

Sources

(8)
+2
GlobeNewsWire The Manila Times Yahoo Finance Nature Genetics New England Journal of Medicine Cancer Research (AACR) Cancer Drug Resistance Broad Institute